Background: The impacts of hypertensive (HTN) donor on the prognosis of simultaneous liver kidney transplantation (SLKT) patient are not known to date, and an applicable risk scoring system for SLKT patient survival is absent in clinic. Our objective was to evaluate the impacts of HTN donors on the prognosis of SLKT patients and to identify independent risk factors associated with patient survival after SLKT.

Methods: SLKT patients from deceased donors from March 2002 to December 2014 in the Scientific Registry of Transplant Recipients (SRTR) database were retrospectively analyzed. Kaplan-Meier analysis was used to compare the patient survival, liver graft and kidney graft survival. Multivariate Cox proportional hazard model was built to identify independent risk factors associated with adult SLKT patient survival, liver graft and kidney graft survival.

Results: SLKT patients receiving HTN donors had significantly shorter 5-year patient survival and kidney graft survival rates than patients receiving non-HTN donors (67.1% vs. 75.8%, p<0.0001 and 85.3% vs. 92.3%, p<0.0001, respectively). Multivariate analysis identified HTN donor, donation after cardiac death (DCD), donor age, liver graft cold ischemia time (CIT), recipient condition at transplant, hepatitis C virus (HCV), need for life support, recipient serum albumin level before transplant, recipient age were independent risk factors associated with SLKT patient survival. A risk scoring model that predicted excellent stratification of prognostic subgroups was established (AUC, 0.762; 95% CI, 0.739-0.785).

Conclusions: SLKT patients receiving HTN donors have inferior patient survival and kidney graft survival compared with patients receiving non-HTN donors. A clinical risk scoring system applicable for SLKT patient survival was developed.

CITATION INFORMATION: Guo Z., Zhu Z., Huang S., Tang Y., Zhang Z., He X., Chen G. Receiving Hypertensive Donor Has an Inferior Prognosis in Simultaneous Liver Kidney Transplantation Recipient Am J Transplant. 2017;17 (suppl 3).

« Back to 2018 American Transplant Congress